Antisense oligodeoxynucleotides (ODNs) have been proposed as a new therapy for patients with cancer, including malignant brain tumors. Antisense ODNs are taken up by tumor cells and selectively block gene expression. Use of ODNs for brain tumors is attractive due to their theoretical specificity, relative ease of production and, to date, paucity of reported adverse effects. This article presents current information regarding antisense ODNs and their possible future use for the treatment of brain tumors.
Methods:
The available published experimental and clinical information regarding antisense ODN treatment of glioblastoma cells and administration into the central nervous system (CNS) was reviewed. Other clinically relevant information pertaining to the molecular biology of antisense ODNs was also collected and summarized.
Results:
Targets for antisense ODN therapy in malignant glioma cells have included c-myc, c-myb, c-sis, c-erb B, CD44, p34cdc2, bFGF, PDGF, TGF-beta, IGF-1, PKC-alpha tumor necrosis factor, urokinase, and S100beta protein. Few in vivo studies of ODN treatment of brain tumors have yet been reported. Systemically administered ODNs enter the brain only in extremely small quantities; therefore, microinfusion into the brain has been recommended.
Conclusions:
Antisense ODNs have been used successfully to block glioblastoma gene expression in vitro and expression of multiple genes within the CNS of experimental animals. Upcoming clinical trials will address the safety of antisense ODN use against malignant brain tumors.
Get full access to this article
View all access options for this article.
References
1.
StephensonM.L., ZamecnikP.C.. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.Proc Natl Acad Sci U S A.1978; 75: 285–288.
2.
HélèneC.. Control of oncogene expression by antisense nucleic acids.Eur J Cancer.1994; 30A: 1721–1726.
3.
AltmannK.H., FabbroD., DeanN.M.. Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors.Biochem Soc Trans.1996; 24: 630–637.
4.
AgrawalS.. Antisense oligonucleotides: towards clinical trials.Tibitech.1996; 14: 376–387.
5.
CohenJ.S.. Oligonucleotides as therapeutic agents.Pharmacol Ther.1991; 52: 211–225.
6.
MilliganJ.F., MatteucciM.D., MartinJ.C.. Current concepts in antisense drug design.J Med Chem.1993; 36: 1923–1937.
MaL., CalvoF.. Recent status of the antisense oligonucleotide approaches in oncology.Fundam Clin Pharmacol.1996; 10: 97–115.
9.
SharmaH.W., NarayananR.. The therapeutic potential of antisense oligonucleotides.Bioessays.1995; 17: 1055–1063.
10.
BryschW., SchlingensiepenK.H.. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.Cell Mol Neurobiol.1994; 14: 557–568.
CalabrettaB.. Inhibition of proto-oncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications.Cancer Res.1991; 51: 4505–4510.
16.
TiddD.M.. Anticancer drug design using modified antisense oligonucleotides. In: MurrayJ.A.H., ed. Antisense RNA and DNA.New York, NY: Wiley-Liss;1992: 227–240.
17.
WagnerR.W.. Gene inhibition using antisense oligodeoxynucleotides.Nature.1994; 372: 333–335.
18.
WickstromE. ed. Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS.New York, NY: Wiley-Liss;1991.
19.
AgrawalS., TemsamaniJ., GalbraithW.. Pharmacokinetics of antisense oligonucleotides.Clin Pharmacokinet.1995; 28: 7–16.
20.
WarzochaK., WotowiecD.. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.Leuk Lymphoma.1997; 24: 267–281.
21.
RedekopG.J., NausC.C.. Transfection with bFGF sense and antisense cDNA resulting in modification of malignant glioma growth.J Neurosurg.1995; 82: 83–90.
22.
AhmadS., MinetaT., MartuzaR.L.. Antisense expression of protein kinase C alpha inhibits the growth and tumorigenicity of human glioblastoma cells.Neurosurgery.1994; 35: 904–908.
23.
ShevelevA., BurfeindP., SchulzeE.. Potential triple helix-mediated inhibition of IGF-I gene expression significantly reduces tumorigenicity of glioblastoma in an animal model.Cancer Gene Ther.1997; 4: 105–112.
24.
SalehM., StackerS.A., WilksA.F.. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.Cancer Res.1996; 56: 393–401.
25.
ChengS.Y., HuangH.J., NaganeM.. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.Proc Natl Acad Sci U S A.1996; 93: 8502–8507.
26.
HallW.A., FloresE.P., LowW.C.. Antisense oligonucleotides for central nervous system tumors.Neurosurgery.1996; 38: 376–383.
27.
SteinC.A., ChengY.C.. Antisense oligonucleotides as therapeutic agents: is the bullet really magical?Science.1993; 261: 1004–1012.
28.
EngelhardH., NarangC., HomerR.. Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity.Biochem Biophys Res Commun.1996; 227: 400–405.
29.
EngelhardH.H., RozentalJ.M.. Status of antisense oligodeoxynucleotides as a novel treatment for malignant glioma.Int J Oncol.1997; 11(suppl): 902.
30.
EngelhardH.H., DuncanH.A., KimS.. Paradoxical and nonspecific effects of antisense treatment of human glioblastoma cells.1998. In press.
31.
AgrawalS., TemsamaniJ., TangJ.Y.. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.Proc Natl Acad Sci U S A.1991; 88: 7595–7599.
32.
BroaddusW.C., ChenZ.J., PrabhuS.S.. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.Neurosurgery.1997; 41: 908–915.
33.
CrookeS.T.. Progress in antisense therapeutics.Med Res Rev.1996; 16: 319–344.
34.
AkhtarS., AgrawalS.. In vivo studies with antisense oligonucleotides.Trends Pharmacol Sci.1997; 18: 12–18.
35.
JachimczakP., HessdorferB., Fabel-SchulteK.. Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligodeoxynucleotides.Int J Cancer.1996; 65: 332–337.
MurrayJ.M., NishikuraK.. Application of antisense nucleic acids in oncology. In: MolJ.N.M., van der KrolA.R., eds. Antisense Nucleic Acids and Proteins.New York, NY: M. Dekker;1991: 95–112.
38.
GryaznovS.M., LloydD.H., ChenJ.K.. Oligonucleotide N3'–>P5’ phosphoramidates.Proc Natl Acad Sci U S A.1995; 92: 5798–5802.
39.
SteinC.A.. Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism.J Natl Cancer Inst.1996; 88: 391–393.
40.
GewirtzA.M., SteinC.A., GlazerP.M.. Facilitating oligonucleotide delivery: helping antisense deliver on its promise.Proc Natl Acad Sci U S A.1996; 93: 3161–3163.
41.
WilliamsS.A., ChangL., BuzbyJ.S.. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.Leukemia.1996; 10: 1980–1989.
42.
CitroG., PerrottiD., CuccoC.. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides.Proc Natl Acad Sci U S A.1992; 89: 7031–7035.
43.
AkhtarS., BasuS., WickstromE.. Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes).Nucleic Acids Res.1991; 19: 5551–5559.
44.
CazenaveC., HeleneC.. Antisense oligonucleotides. In: MolJ.N.M., van der KrolA.R., eds. Antisense Nucleic Acids and Proteins.New York, NY: M. Dekker;1991; 47-93.
45.
CarterG., LemoineN.R.. Antisense technology for cancer therapy: does it make sense?Br J Cancer.1993; 67: 869–876.
46.
GuraT.. Antisense has growing pains.Science.1995; 270: 575–577.
47.
AggarwalB.B., SchwarzL., HoganM.E.. Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells.Cancer Res.1996; 56: 5156–5164.
48.
EngL.F.. Current antisense nucleic acid strategies for manipulating neuronal and glial cells.Antisense Nucleic Acid Technology.New York, NY: Raven Press Ltd; 1993: 293–310.
49.
OkadaT., YamaguchiK., YamashitaY.. Triplex-forming oligonucleotide binding represses transcription of the human c-erbB gene in glioma.Growth Factors.1994; 11: 259–270.
50.
BehlC., WinklerJ., BogdanU.. Autocrine growth regulation in neuroectodermal tumors as detected with oligodeoxynucleotide antisense molecules.Neurosurgery.1993; 33: 679–684.
51.
ResnicoffM., SellC., RubiniM.. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors.Cancer Res.1994; 54: 2218–2222.
52.
NittaT., SatoK.. Specific inhibition of c-sis protein synthesis and cell proliferation with antisense oligodeoxynucleotides in human glioma cells.Neurosurgery.1994; 34: 309–314.
53.
YazakiT., AhmadS., ChahlaviA.. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.Mol Pharmacol.1996; 50: 236–242.
54.
YungW.K.. New approaches in brain tumor therapy using gene transfer and antisense oligonucleoides.Curr Opin Oncol.1994; 6: 235–239.
55.
BaltuchG.H., DooleyN.P., RostworowskiK.M.. Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation.J Neurooncol.1995; 24: 241–250.
56.
MercerW.E., UllrichS.J., ShieldsM.T.. Cell cycle effects of microinjected antisense oligodeoxynucleotides to p34cdc2 kinase.Ann N Y Acad Sci.1992; 660: 209–218.
57.
MerzakA., KoocheckpourS., PilkingtonG.J.. CD44 mediates human glioma cell adhesion and invasion in vitro.Cancer Res.1994; 54: 3988–3992.
58.
MorrisonR.S.. Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes.J Biol Chem.1991; 266: 728–734.
59.
MurphyP.R., SatoY., KneeR.S.. Phosphorothioate antisense oligonucleotides against basic fibroblast growth factor inhibit anchorage-dependent and anchorage-independent growth of a malignant glioblastoma cell line.Mol Endocrinol.1992; 6: 877–884.
60.
SelinfreundR.H., BargerS.W., WelshM.J.. Antisense inhibition of glial S100 beta production results in alterations in cell morphology, cytoskeletal organization and cell proliferation.J Cell Biol.1990; 111: 2021–2028.
61.
Van EldikL.J., BargerS.W., WelshM.J.. Antisense approaches to the function of glial cell proteins.Ann N Y Acad Sci.1992; 660: 219–230.
62.
BurgessT.L., FisherE.F., RossS.L.. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism.Proc Natl Acad Sci U S A.1995; 92: 4051–4055.
63.
ChavanyC., ConnellY., NeckersL.. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers.Mol Pharmacol.1995; 48: 738–746.
64.
MahonF.X., RipocheJ., PigeonnierV.. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.Exp Hematol.1995; 23: 1606–1611.
65.
WeidnerD.A., BuschH.. Antisense phosphorothioate oligonucleotides direct both site-specific and nonspecific RNAse H cleavage of in vitro synthesized p120 mRNA.Oncol Res.1994; 6: 237–242.
66.
JanicekM.F., AngioliR., UnalA.D.. p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.Gynecol Oncol.1997; 66: 94–102.
67.
SaijoY., UchiyamaB., AbeT.. Contiguous four-guanosine sequence in c-myc antisense phosphorothioate oligonucleotides inhibits cell growth on human lung cancer cells: possible involvement of cell adhesion inhibition.Jpn J Cancer Res.1997; 88: 26–33.
68.
RockwellP., O'ConnerW.J., KingK.. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides.Proc Natl Acad Sci U S A.1997; 94: 6523–6528.
69.
HartmannG., KrugA., EiglerA.. Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides.Antisense Nucleic Acid Drug Dev.1996; 6: 291–299.
70.
PerezJ.R., LiY., SteinC.A.. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides.Proc Natl Acad Sci U S A.1994; 91: 5957–5961.
71.
HoP.T., IshiguroK., WickstromE.. Non-sequence-specific inhibition of transferrin receptor expression in HL-60 leukemia cells by phosphorothioate oligodeoxynucleotides.Antisense Res Dev.1991; 1: 329–342.
72.
WoolfT.M., JenningsC.G., RebagliatiM.. The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos.Nucleic Acid Res.1990; 18: 1763–1769.
73.
LevyR.M., WardS., SchalgeterK.. Alternative delivery systems for antiviral nucleosides and antisense oligonucleotides to the brain.J Neuro Virology.1997; 3: S74–S75.
74.
WojcikW.J., SwovelandP., ZhangX.. Chronic intrathecal infusion of phosphorothioate or phosphodiester antisense oligonucleotides against cytokine responsive gene-2/IP-10 in experimental allergic encephalomyelitis of Lewis rat.J Pharmacol Exp Ther.1996; 278: 404–410.
75.
WhitesellL., GeselowitzD., ChavanyC.. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system.Proc Natl Acad Sci U S A.1993; 90: 4665–4669.
76.
YaidaY., NowakTSJr. Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization.Regul Pept.1995; 59: 193–199.
77.
SzklarczykA., KaczmarekL.. Antisense oligodeoxyribonucleotides: stability and distribution after intracerebral injection into rat brain.J Neurosci Methods.1995; 60: 181–187.
78.
OgawaS., BrownH.E., OkanoH.J.. Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain.Regul Pept.1995; 59: 143–149.
79.
YeeF., EricsonH., ReisD.J.. Cellular uptake of intracerebroventricularly administered biotin- or digoxigenin-labeled antisense oligodeoxynucleotides in the rat.Cell Mol Neurobiol.1994; 14: 475–486.
80.
SunF.Y., FadenA.I.. Pretreatment with antisense oligodeoxynucleotides directed against the NMDA-R1 receptor enhances survival and behavioral recovery following traumatic brain injury in rats.Brain Res.1995; 693: 163–168.
81.
BilskyE.J., BernsteinR.N., HrubyV.J.. Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated “knock-down” of opioid receptor in vivo.J Pharmacol Exp Ther.1996; 277: 491–501.
82.
EdsallS.A., KnappR.J., VanderahT.W.. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception.Neuroreport.1996; 7: 593–596.
83.
SkutellaT., SchwartingR.K.W., HustonJ.P.. Infusions of tyrosine hydroxylase antisense oligodeoxynucleotide into substantia nigra of the rat: effects on tyrosine hydroxylase mRNA and protein content, striatal dopamine release and behaviour.Eur J Neurosci.1997; 9: 210–220.
84.
QuerciaS., ChangS.L.. Antisense oligodeoxynucleotide attenuates in vivo expression of c-fos in the paraventricular hypothalamic nucleus of the rat brain.Neurosci Lett.1996; 209: 89–92.
85.
ZapataA., CapdevilaJ.L., TarrasonG.. Effects of NMDA-R1 antisense oligodeoxynucleotide administration: behavioral and radioligand binding studies.Brain Res.1997; 745: 114–120.
86.
AguanK., MeheshV.B., PingL.. Evidence for a physiological role for nitric oxide in the regulation of the LH surge: effect of central administration of antisense oligonucleotides to nitric oxide synthase.Neuroendocrinology.1996; 64: 449–455.
87.
OgawaS., OlazabalU.E., ParharI.S.. Effects of intrahypothalamic administration of antisense DNA for progesterone receptor mRNA on reproductive behavior and progesterone receptor immunoreactivity in female rat.J Neurosci.1994; 14: 1766–1774.
88.
SakaiR.R., MaL.Y., HeP.F.. Intracerebroventricular administration of angiotensin type 1 (AT1) receptor antisense oligonucleotides attenuate thirst in the rat.Regul Pept.1995; 59: 183–192.
89.
SakaiR.R., HeP.F., YangX.D.. Intracerebroventricular administration of AT1 receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II.J Neurochem.1994; 62: 2053–2056.
90.
McCarthyM.M., MastersD.B., RimvallK.. Intracerebral administration of antisense oligodeoxynucleotides to GAD65 and GAD67 mRNAs modulate reproductive behavior in the female rat.Brain Res.1994; 636: 209–220.
91.
GuzowskiJ.F., McGaughJ.L.. Antisense oligodeoxynucleotide-mediated disruption of hippocampal cAMP response element binding protein levels impairs consolidation of memory for water maze training.Proc Natl Acad Sci U S A.1997; 94: 2693–2698.
92.
ZhouL.W., ZhangS.P., WeissB.. Intrastriatal administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor mRNA inhibits D2 dopamine receptor-mediated behavior and D2 dopamine receptors in normal mice and in mice lesioned with 6-hydroxydopamine.Neurochem Int.1996; 29: 583–595.
93.
ReulJ.M., ProbstJ.C., SkutellaT.. Increased stress-induced adrenocorticotropin response after long-term intracerebroventricular treatment of rats with antisense mineralocorticoid receptor oligodeoxynucleotides.Neuroendocrinology.1997; 65: 189–199.
94.
AkabayashiA., WahlestedtC., AlexanderJ.T.. Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion.Brain Res Mol Brain Res.1994; 21: 55–61.
95.
WielboD., SerniaC., GyurkoR.. Antisense inhibition of hypertension in the spontaneously hypertensive rat.Hypertension.1995; 25: 314–319.
96.
LandgrafR., GerstbergerR., MontkowksiA.. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats.J Neurosci.1995; 15: 4250–4258.
97.
HulseyM.G., PlessC.M., WhiteB.D.. ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release.Regul Pept.1995; 59: 207–214.
98.
Sanchez-BlazquezP., Garcia-EspanaA., GarzonJ.. In vivo injection of antisense oligodeoxynucleotides to G alpha subunits and supraspinal analgesia evoked by mu and delta opioid agonists.J Pharmacol Exp Ther.1995; 275: 1590–1596.
99.
PezeshkiG., SchobitzB., PohlT.. Intracerebroventricular administration of missense oligodeoxynucleotide induces interleukin-6 mRNA expression in brain and spleen of rats.Neurosci Lett.1996; 217: 97–100.
100.
YamadaK., MoriguchiA., MorishitaR.. Efficient oligonucleotide delivery using the HVJ-liposome method in the central nervous system.Am J Physiol.1996; 271: R1212–1220.
101.
WickstromE., BaconT.A., WickstromE.L.. Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates.Cancer Res.1992; 52: 6741–6745.
102.
WhitesellL., RosolenA., NeckersL.M.. In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide.Antisense Res Dev.1991; 1: 343–350.
103.
KitajimaI., ShinoharaT., BilakovicsJ.. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B.Science.1992; 258: 1792–1795.
104.
BayeverE., IversenP., SmithL.. Guest editorial: systemic human antisense therapy begins.Antisense Res Dev.1992; 2: 109–110.
105.
BishopM.R., IversenP.L., BayeverE.. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.J Clin Oncol.1996; 14: 1320–1326.
